T2 Biosystems, Inc. (TTOO)
Largest Insider Buys in Sector
TTOO Stock Price History Chart
TTOO Stock Performance
About T2 Biosystems, Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream …
Insider Activity of T2 Biosystems, Inc.
Over the last 12 months, insiders at T2 Biosystems, Inc. have bought $0 and sold $133 worth of T2 Biosystems, Inc. stock.
On average, over the past 5 years, insiders at T2 Biosystems, Inc. have bought $47,937 and sold $2.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,952 shares for transaction amount of $6,476 was made by Barclay Alec (Chief Operations Officer) on 2022‑04‑08.
List of Insider Buy and Sell Transactions, T2 Biosystems, Inc.
| 2024-09-13 | Sale | director | 55 0.0003% | $2.42 | $133 | -70.12% | ||
| 2023-09-28 | Sale | 10 percent owner | 1.94M 0.5132% | $0.16 | $305,212 | -5.51% | ||
| 2023-09-27 | Sale | 10 percent owner | 5.98M 1.8991% | $0.19 | $1.15M | -5.51% | ||
| 2023-09-26 | Sale | 10 percent owner | 5.39M 1.5921% | $0.20 | $1.08M | -5.51% | ||
| 2023-09-25 | Sale | 10 percent owner | 250,000 0.0854% | $0.25 | $62,500 | -5.51% | ||
| 2023-09-22 | Sale | 10 percent owner | 5.08M 1.5515% | $0.26 | $1.31M | -5.51% | ||
| 2023-09-21 | Sale | 10 percent owner | 6.34M 1.9818% | $0.30 | $1.9M | -5.51% | ||
| 2023-09-20 | Sale | 10 percent owner | 7.75M 2.393% | $0.31 | $2.41M | -5.51% | ||
| 2023-09-19 | Sale | 10 percent owner | 10.4M 3.3665% | $0.37 | $3.81M | -5.51% | ||
| 2023-03-28 | Sale | General Counsel | 239 <0.0001% | $0.48 | $115 | -5.51% | ||
| 2023-02-28 | Sale | Chairman and CEO | 2,898 <0.0001% | $0.59 | $1,710 | -5.51% | ||
| 2023-02-28 | Sale | Chief Financial Officer | 1,148 <0.0001% | $0.59 | $677 | -5.51% | ||
| 2023-02-28 | Sale | General Counsel | 1,585 <0.0001% | $0.59 | $935 | -5.51% | ||
| 2023-02-22 | Sale | Chairman and CEO | 6,875 <0.0001% | $0.65 | $4,469 | -5.51% | ||
| 2023-02-22 | Sale | Chief Financial Officer | 1,545 <0.0001% | $0.65 | $1,004 | -5.51% | ||
| 2023-02-22 | Sale | General Counsel | 2,145 <0.0001% | $0.65 | $1,394 | -5.51% | ||
| 2023-02-22 | Sale | Chief Commercial Officer | 537 <0.0001% | $0.65 | $349 | -5.51% | ||
| 2023-02-20 | Sale | Chief Commercial Officer | 537 <0.0001% | $0.65 | $349 | -5.51% | ||
| 2022-11-10 | Sale | Chief Commercial Officer | 1,292 0.0246% | $1.79 | $2,317 | |||
| 2022-04-08 | Chief Operations Officer | 12,951.88 0.0076% | $0.50 | $6,476 | -81.61% |
Institutional Investor Ownership
| The Vanguard Group | $137,085.00 | 0.3 | 45,695 | 0% | +$0 | <0.0001 | |
| Susquehanna International Group | $123,498.00 | 0.27 | 41,166 | -25.16% | -$41,514.00 | <0.0001 | |
| BlackRock | $110,883.00 | 0.24 | 36,961 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $83,538.00 | 0.18 | 27,840 | +15.74% | +$11,360.45 | <0.0001 | |
| Virtu Financial Llc | $39,000.00 | 0.09 | 13,096 | +29.95% | +$8,987.63 | <0.01 |